Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

SHE:300497 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	491.58	482.98	695.35	729.37	978.03	1,272
Trading Asset Securities	0.82	0.95	2.19	2.19	49.74	150.76
Cash & Short-Term Investments	492.4	483.93	697.54	731.56	1,028	1,423
Cash Growth	-19.11%	-30.62%	-4.65%	-28.82%	-27.79%	-15.88%
Accounts Receivable	807.92	533.29	498.16	572.92	552.49	376.21
Other Receivables	45.1	47.35	53.85	128.31	78.21	80.01
Receivables	853.02	580.64	552.01	701.23	630.71	456.22
Inventory	394.29	379.93	421.05	434.68	553.69	416.15
Other Current Assets	7.49	16.84	10.42	9.97	17.11	15.97
Total Current Assets	1,747	1,461	1,681	1,877	2,229	2,312
Property, Plant & Equipment	2,253	2,290	2,267	2,331	2,201	1,857
Long-Term Investments	272	271.31	255.9	271.27	271.42	133.02
Goodwill	-	-	-	-	1.15	2.22
Other Intangible Assets	298.43	287.85	235	241.07	249.71	256.32
Long-Term Deferred Tax Assets	36.52	34.8	37.26	29.37	28.49	27.54
Other Long-Term Assets	80.97	59.69	60.95	69.13	78.79	90.82
Total Assets	4,688	4,405	4,537	4,819	5,060	4,678

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	403.24	348.04	603.37	581.93	656.67	517.05
Accrued Expenses	31.31	36.71	44.05	44.52	42.4	51.97
Short-Term Debt	731.46	571.5	556.4	549.83	366.74	615.18
Current Portion of Long-Term Debt	45.84	270.02	311.78	78.78	7.96	33.5
Current Income Taxes Payable	0.03	0.06	0.05	0.82	8.71	13.89
Current Unearned Revenue	1.78	2.43	2.72	3.4	1.42	1.82
Other Current Liabilities	141.84	40.49	25.46	26.32	174.96	126.56
Total Current Liabilities	1,363	1,269	1,544	1,286	1,259	1,360
Long-Term Debt	799.61	809.46	736.48	998.26	1,043	353
Long-Term Unearned Revenue	126.56	123.97	77.67	62.39	62.03	50.3
Long-Term Deferred Tax Liabilities	1.82	1.86	1.96	2.05	6.27	3.92
Total Liabilities	2,306	2,205	2,360	2,348	2,370	1,767

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	538.65	538.65	550	550	550	550
Additional Paid-In Capital	1,250	1,247	1,381	1,414	1,408	1,406
Retained Earnings	530.7	353.75	408.78	680.88	881.68	1,023
Treasury Stock	-	-	-174.86	-174.86	-174.86	-105.11
Comprehensive Income & Other	44.48	44.33	15.45	14.3	16.89	6.08
Total Common Equity	2,364	2,184	2,180	2,485	2,681	2,880
Minority Interest	18.74	16.38	-3.54	-14.06	8.4	31.1
Shareholders' Equity	2,383	2,200	2,177	2,471	2,690	2,911
Total Liabilities & Equity	4,688	4,405	4,537	4,819	5,060	4,678

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	1,599	1,651	1,605	1,627	1,418	1,002
Net Cash (Debt)	-1,107	-1,167	-907.13	-895.31	-389.97	421.54
Net Cash Growth	-	-	-	-	-	-66.26%
Net Cash Per Share	-2.34	-2.12	-1.70	-1.65	-0.72	0.78
Filing Date Shares Outstanding	538.65	538.65	538.65	538.65	538.65	538.65
Total Common Shares Outstanding	538.65	538.65	538.65	538.65	538.65	543.13
Working Capital	383.7	192.09	137.2	591.84	970.42	951.59
Book Value Per Share	4.39	4.05	4.05	4.61	4.98	5.30
Tangible Book Value	2,065	1,896	1,945	2,244	2,430	2,622
Tangible Book Value Per Share	3.83	3.52	3.61	4.17	4.51	4.83
Buildings	1,108	1,030	936.67	836.72	712.09	471.86
Machinery	1,883	1,773	1,641	1,423	1,232	851.39
Construction In Progress	295.61	428.95	457.86	695.78	736.4	922.19

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 18, 2026

Data Sources Report a data error